Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

CEC.5/Alliance A221208 - Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases

The primary objective of CEC.5 is to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms (clinical and patient-reported symptom improvement associated with radionecrosis and less radionecrosis treatment-induced symptoms) compared with standard corticosteroid therapy.

Secondary objectives are to:
  • Evaluate the toxicity profile associated with bevacizumab and corticosteroid therapy;
  • Compare self-reported health-related quality of life (HRQOL) using LASA, Dexamethasone Symptoms Questionnaire-Chronic (DSQ-C), and MDASI-BT symptom and interference score between treatment arms;
  • Compare intracranial progression-free survival and time to maximum radiographic response between treatment arms; and,
  • Compare the dose and duration of corticosteroids required between treatment arms and correlate steroid requirement with DSQ-C and MDASI-BT scores.
Correlative objectives are to:
  • Explore serum/urine biomarkers that predict for treatment response; and,
  • Explore early imaging biomarkers that predict for treatment response.
Total sample size is 130 patients. Centres interested in participating in this trial should contact Sarah Hunter, Study Coordinator, at shunter@ctg.queensu.ca.
____________________________

OVC.1/NRG-GY0004 - A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The primary objective of this trial is to assess the efficacy of either single agent olaparib or the combination of cediranib and olaparib, as measured by progression-free survival, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.

The secondary objective is to assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by response rate, and overall survival as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.

Total sample size is 450 patients. Centres interested in participating in this trial should contact Wenling Liu at wliu@ctg.queensu.ca.
____________________________

GA.3/AGITG-AG0315OG - A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

The primary objective of this trial is to determine the effect of regorafenib on overall survival (death from any cause) in the overall study population and in the Asian sub-population.

Secondary objectives are to determine the effect of regorafenib on:
  • Progression-free survival (disease progression or death);
  • Objective tumour response rate (partial or complete response);
  • Quality of life(scores from participant-completed questionnaires); and,
  • Safety (rates of adverse events).
Total sample size is 350 patients. Centres interested in participating in this trial should contact Maaike Hum at mhum@ctg.queensu.ca.